Suraksha Diagnostic Ltd.
SURAKSHA.BO
Bombay Stock Exchange264.25
INR
+0.90
- -
Suraksha Diagnostic Ltd.
SURAKSHA.BO
(Bombay Stock Exchange)
Recent
price
264.25
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Suraksha Diagnostic Limited operates as an integrated diagnostic services provider in eastern India, offering pathology and radiology testing alongside medical consultation services through an extensive network that includes a central reference laboratory, eight satellite laboratories, approximately 55 diagnostic centers, and over 166 sample collection centers primarily across West Bengal, Bihar, Assam, and Meghalaya; the company serves a predominantly business-to-consumer market with a test menu encompassing more than 2,300 offerings such as routine and specialized pathology tests including microbiology, serology, molecular biology, histopathology, cytogenetics, advanced biochemistry, and hematology; basic, intermediate, and advanced radiology tests featuring X-rays, ultrasonography, CT scans, and MRI supported by 24 CT and 13 MRI machines; cardiology including stress tests, neurology, gastroenterology, and customized health packages for early disease detection alongside vaccination services; omnichannel consultations via 120 polyclinic chambers hosting over 750 specialist doctors across specialties like cardiology, pediatrics, dermatology, rheumatology, oncology, nephrology, gynecology, and general surgery. Founded in 2005 and headquartered in Kolkata, West Bengal, Suraksha Diagnostic maintains accreditations from the College of American Pathologists for its central lab, NABL for select laboratories, and NABH for advanced centers, leveraging advanced equipment from vendors including Siemens Healthineers, Wipro GE Healthcare, Roche Diagnostics, and Phillips India; the company emphasizes technological infrastructure such as Laboratory Information Management System, Radiology Information System, Picture Archive Communication System, and digital pathology with AI for efficient reporting and home sample collection. Recent developments include a successful initial public offering in December 2024 raising Rs 846.25 crore to fund expansion; acquisition of 63% stake in Fetomat Wellness Private Limited in April 2025 to enter genomic medicine and enhance maternal-fetal care capabilities; addition of seven new centers under public-private partnership models bringing the total to 55 diagnostic centers as of March 2025; and ongoing capital expenditures increasing fixed assets while serving 1.14 million patients with 5.98 million tests in fiscal 2024.